Clinical Trial Update: Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update of the combination of oleclumab and durvalumab for recurrent, refractory, or metastatic sarcoma, including angiosarcoma, dediffere…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angiosarcoma
• Dedifferentiated Liposarcoma
• Osteosarcoma

Drugs mentioned

• Durvalumab (durvalumab)
• Oleclumab (oleclumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Angiosarcoma, Metastatic Dedifferentiated Liposarcoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING